COVID-19 Update - This is to inform you that the Government of India has announced a complete lockdown in India 22nd March 2020 to 3rd May 2020. As a result, our offices will now be closed till 3rd May 2020 and all our employees will be working from home. Office telephones will not be answered, and therefore you are requested to direct all your queries related to manuscript submission, review process, publication etc. at below mentioned details.,, Mob. 8826373757, 8826859373, 9910947804

Print ISSN:-2394-2789

Online ISSN:-2394-2797


Current Issue

Year 2020

Volume: 7 , Issue: 1

Article Access statistics

Viewed: 480

Emailed: 0

PDF Downloaded: 206

International Journal of Pharmaceutical Chemistry and Analysis

Bedaquiline –A new drug against multidrug-resistant tuberculosis

Full Text PDF Share on Facebook Share on Twitter

Author Details : Sankalp Yadav, Gautam Rawal

Volume : 5, Issue : 2, Year : 2018

Article Page : 106-107

Suggest article by email


The infectious diseases have taken a toll on the rapidly multiplying population of the developing countries. The top three killers being HIV AIDS, TB and malaria. The total number of deaths due to TB is really a cause of concern since a well laid national program is running in most of these countries. However, even in the presence of clear guidelines to treat TB, there has always been a gradual rise in the new cases with few exceptions in some of these resource-constrained countries. The issue becomes graver when the problem of drug-resistant TB also comes into the picture. In the present article, the authors highlight the introduction of the new drug i.e., Bedaquiline in India to counter the problem of multidrug-resistant TB.

Keywords: Bedaquiline, Drug; Drug-resistant, TB; Tuberculosis

Doi : 10.18231/2394-2797.2018.0017

How to cite : Yadav S, Rawal G, Bedaquiline –A new drug against multidrug-resistant tuberculosis. Int J Pharm Chem Anal 2018;5(2):106-107

Copyright © 2018 by author(s) and Int J Pharm Chem Anal. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0) (